Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.

Anderson KG, Voillet V, Bates BM, Chiu EY, Burnett MG, Garcia NM, Oda SK, Morse CB, Stromnes IM, Drescher CW, Gottardo R, Greenberg PD.

Cancer Immunol Res. 2019 Sep;7(9):1412-1425. doi: 10.1158/2326-6066.CIR-19-0258. Epub 2019 Jul 23.

PMID:
31337659
2.

A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia.

Oda SK, Daman AW, Garcia NM, Wagener F, Schmitt TM, Tan X, Chapuis AG, Greenberg PD.

Blood. 2017 Nov 30;130(22):2410-2419. doi: 10.1182/blood-2017-04-777052. Epub 2017 Oct 17.

3.

Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response.

Hu J, Oda SK, Shotts K, Donovan EE, Strauch P, Pujanauski LM, Victorino F, Al-Shami A, Fujiwara Y, Tigyi G, Oravecz T, Pelanda R, Torres RM.

J Immunol. 2014 Jul 1;193(1):85-95. doi: 10.4049/jimmunol.1300429. Epub 2014 Jun 2.

4.

Alternative splice forms of CTLA-4 induced by antisense mediated splice-switching influences autoimmune diabetes susceptibility in NOD mice.

Mourich DV, Oda SK, Schnell FJ, Crumley SL, Hauck LL, Moentenich CA, Marshall NB, Hinrichs DJ, Iversen PL.

Nucleic Acid Ther. 2014 Apr;24(2):114-26. doi: 10.1089/nat.2013.0449. Epub 2014 Feb 4.

PMID:
24494586
5.

Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.

Oda SK, Strauch P, Fujiwara Y, Al-Shami A, Oravecz T, Tigyi G, Pelanda R, Torres RM.

Cancer Immunol Res. 2013 Oct;1(4):245-55. doi: 10.1158/2326-6066.CIR-13-0043-T.

6.

Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing.

Marshall NB, Oda SK, London CA, Moulton HM, Iversen PL, Kerkvliet NI, Mourich DV.

J Immunol Methods. 2007 Aug 31;325(1-2):114-26. Epub 2007 Jul 27.

PMID:
17673254

Supplemental Content

Support Center